Copyright
©The Author(s) 2020.
World J Gastroenterol. Feb 14, 2020; 26(6): 598-613
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.598
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.598
Drugs | Treatment sequence and result of FA and median effect plot analysis | FA | |||
0.5 | 0.75 | 0.95 | |||
Cisplatin and VPA | Pre | Dose of Cis, VPA (µmol/L) | 0.965, 386.359 | 2.711, 1084.65 | 15.361, 6144.61 |
CI | 0.352 | 0.471 | 0.784 | ||
Concurrent | Dose of Cis, VPA (µmol/L) | 0.705, 282.387 | 3.874, 1549.74 | 67.690, 27076.0 | |
CI | 0.257 | 0.673 | 3.454 | ||
Post | Dose of Cis, VPA (µmol/L) | 3.254 ,1301.90 | 9.362, 3745.16 | 55.260, 22104.1 | |
CI | 1.188 | 1.627 | 2.820 | ||
Oxaliplatin and VPA | Pre | Dose of Oxa, VPA (µmol/L) | 0.788, 394.469 | 2.094, 1047.04 | 10.796, 5398.39 |
CI | 0.404 | 0.453 | 0.552 | ||
Concurrent | Dose of Oxa, VPA (µmol/L) | 1.533, 766.633 | 4.305, 2152.92 | 24.406, 12203.2 | |
CI | 0.786 | 0.933 | 1.249 | ||
Post | Dose of Oxa, VPA (µmol/L) | 2.362, 1181.47 | 8.451, 4225.64 | 71.917, 35958.6 | |
CI | 1.211 | 1.83182 | 3.68265 | ||
Epirubicin and TSA | Pre | Combined dose (µg) | 0.030, 0.300 | 0.093, 0.931 | 0.623, 6.231 |
CI | 0.645 | 0.727 | 1.222 | ||
Concurrent | Combined dose (µg) | 0.129, 1.299 | 0.410, 4.105 | 2.835, 28.356 | |
CI | 2.789 | 3.207 | 5.563 | ||
Post | Combined dose (µg) | 0.137, 1.375 | 0.301, 3.010 | 1.122, 11.220 | |
CI | 2.952 | 2.351 | 2.201 |
- Citation: Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol 2020; 26(6): 598-613
- URL: https://www.wjgnet.com/1007-9327/full/v26/i6/598.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i6.598